2m 2m 2m 2m 2m 2m 2m
Alnylam Pharma (ALNY)
NASDAQ
$288.25+$1.83 (+0.64%)
Price as of Jun 23, 2026 5:54 PM EDT- $38.2BMarket Cap
- -8.53%1-Year Change
- BiotechnologyIndustry
Alnylam Pharma (ALNY)
$288.25+$1.83 (+0.64%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 3.0B +32.84% | 2.2B +22.97% | 1.8B +76.23% | 1.0B +22.88% | |
Cost of Revenue | 677.2M +120.93% | 306.5M +14.28% | 268.2M +91.35% | 140.2M +21.89% | |
Gross Profit | 2.3B +18.93% | 1.9B +24.46% | 1.6B +73.87% | 897.2M +23.03% | |
Sales and Marketing Expense | 1.2B +24.11% | 975.5M +22.61% | 795.6M +3.24% | 770.7M +24.17% | |
Research and Development Expense | -1.3B +17.19% | -1.1B +12.13% | -1.0B +13.75% | -883.0M +11.47% | |
Depreciation and Amortization Expense | 55.7M -1.79% | 56.7M +4.84% | 54.1M +21.56% | 44.5M -6.52% | |
Total Operating Expenses | 3.2B +32.46% | 2.4B +14.91% | 2.1B +15.80% | 1.8B +17.36% | |
Operating Profit | 501.6M +383.56% | -176.9M -37.31% | -282.2M -64.06% | -785.1M +10.78% | |
Interest Income | 111.5M -8.63% | 122.0M +27.66% | 95.6M N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | -121.2M -22.28% | -156.0M +9.05% | |
Interest Income and Expense and Net | 111.5M -8.63% | 122.0M +575.42% | -25.7M -83.55% | -156.0M +10.27% | |
Total Nonoperating Income and Expense | -178.4M -11.01% | -200.5M +32.47% | -151.3M -55.74% | -341.9M +138.29% | |
Income before Taxes | 323.2M +185.63% | -377.4M -12.95% | -433.5M -61.53% | -1.1B +32.25% | |
Income Taxes | 9.4M +109.48% | -99.2M -1,575.36% | 6.7M +61.54% | 4.2M +512.21% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | 313.7M +212.79% | -278.2M -36.82% | -440.2M -61.08% | -1.1B +32.64% | |
Net Income from Continuing Operations Applicable to Common | 323.2M +185.63% | -377.4M -12.95% | -433.5M -61.53% | -1.1B +32.25% | |
Basic EPS and Net Income | 2.39 +209.63% | -2.18 -38.07% | -3.52 -62.15% | -9.30 +29.17% | |
Diluted EPS and Net Income | 2.33 +206.88% | -2.18 -38.07% | -3.52 -62.15% | -9.30 +29.17% | |
Basic Weighted Average Shares | 131.0M +2.63% | 127.7M +2.20% | 124.9M +2.64% | 121.7M +2.73% | |
Diluted Weighted Average Shares | 134.7M +5.51% | 127.7M +2.20% | 124.9M +2.64% | 121.7M +2.73% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 1.7B +71.48% | 966.4M +18.92% | 812.7M -6.20% | 866.4M +5.66% | |
Short-Term Investments | 1.3B -27.25% | 1.7B +6.46% | 1.6B +24.47% | 1.3B -16.19% | |
Cash and Cash Equivalents and Short-Term Investments | 2.9B +8.27% | 2.7B +10.63% | 2.4B +12.19% | 2.2B -8.63% | |
Total Current Assets | 4.1B +22.92% | 3.3B +10.48% | 3.0B +10.79% | 2.7B -4.14% | |
Accumulated Depreciation | 322.7M +19.36% | 270.4M +21.20% | 223.1M +28.61% | 173.4M +23.53% | |
Property and Plant and Equipment and Net | 513.1M +2.06% | 502.8M -4.42% | 526.1M +0.49% | 523.5M +4.29% | |
Total Long-Term Assets | 59.5M -8.96% | 65.3M -9.30% | 72.0M +8.94% | 66.1M +9.78% | |
Total Assets | 5.0B +17.13% | 4.2B +10.71% | 3.8B +7.99% | 3.5B -2.66% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Current Liabilities | 1.5B +23.61% | 1.2B +22.58% | 967.8M +26.03% | 767.9M +10.38% | |
Total Long-Term Debt | 1.0B -1.64% | 1.0B +0.38% | 1.0B +0.38% | 1.0B +50.50% | |
Total Long-Term Liabilities | 7.6M -98.09% | 398.1M +29.07% | 308.4M +45.09% | 212.6M +114.81% | |
Total Liabilities | 4.2B +0.10% | 4.2B +3.02% | 4.1B +9.34% | 3.7B +21.26% | |
Retained Earnings | -6.7B -8.03% | -7.3B +3.97% | -7.0B +6.70% | -6.6B +20.80% | |
Total Stockholders Equity | 789.2M +1,076.33% | 67.1M +130.41% | -220.6M +39.45% | -158.2M -126.90% | |
Total Shares Outstanding | 132.4M +2.38% | 129.3M +2.78% | 125.8M +1.51% | 123.9M +3.11% | |
Cash Flow | |||||
Cash from Operating Activities | 524.1M +6,405.10% | -8.3M -107.98% | 104.2M +119.24% | -541.3M -15.65% | |
Capital Expenditures | 58.7M +71.24% | 34.3M -44.90% | 62.2M -13.67% | 72.1M -5.65% | |
Cash from Investing Activities | 436.3M +473.44% | -116.8M -65.26% | -336.4M -298.61% | 169.4M +161.97% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | -305.2M -203.75% | 294.2M +70.89% | 172.1M -59.57% | 425.8M -65.86% | |
Financials Ratio | |||||
Gross Margin | 77.33% -10.47% | 86.37% +1.22% | 85.33% -1.34% | 86.49% +0.13% | |
Operating Margin | 16.79% +313.46% | -7.87% -49.02% | -15.43% -79.61% | -75.68% -9.84% | |
Return on Assets | 6.82% +198.87% | -6.89% -42.25% | -11.94% -62.06% | -31.47% +30.07% | |
Return on Equity | 73.28% -79.77% | 362.29% +55.89% | 232.40% +144.17% | -526.14% +394.93% | |
Revenue Growth | 32.84% +42.97% | 22.97% -69.87% | 76.23% +233.27% | 22.88% -67.92% | |
Current Ratio | 2.76 -0.55% | 2.78 -9.87% | 3.08 -12.09% | 3.51 -13.16% | |
Cash Ratio | 1.13 +38.73% | 0.81 -2.98% | 0.84 -25.57% | 1.13 -4.28% | |
Debt-to-Equity Ratio | 1.28 N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.20 N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow